Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Smith, Melody, García-Martínez, Elena, Pitter, Michael R., Fucikova, Jitka, Spisek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2018
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279325/
https://ncbi.nlm.nih.gov/pubmed/30524908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1526250
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares